“恆大系”股票漲幅擴大 中國恆大(3333.HK)漲超13%
格隆匯9月30日丨全線高開的恆大系股票開盤後漲幅進一步擴大,截至目前,中國恆大漲超13%,恆騰網絡漲近9%,恆大汽車漲近8%,恆大地產集團存續債連續第三日反彈,“19恆大02”和“19恆大01”均漲逾6%。此外,恆大產業鏈股票(家居裝修類)也普遍上漲,江山歐派漲停,金螳螂等有明顯上漲。公司昨晚公告,近日與持有恆大地產總額1300億元的戰略投資者進行商談,29日與持有恆大地產總額863億元的戰略投資者簽訂補充協議,這些戰略投資者已同意不進行回購,繼續持有恆大地產權益,股權比例保持不變。剩餘的437億元戰投中,公司已與155億元戰投商談完畢,正在辦理審批手續,還有282億元戰投仍在商談中。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.